Innovations of two Bangladeshi researchers in hepatitis B treatment

Two researchers have developed more effective and better medicines for the treatment of people infected with hepatitis B virus. If the approval of the Directorate of Drug Administration, it will be marketed at the beginning of next year.

Professor of Hepatology Department of Bangabandhu Sheikh Mujib Medical University Mamun-al-Mahtab and expatriate Bangladeshi lever specialist Professor Dr. Sheikh Mohammad Fazle Akbar invented the new type of drug 'NASAVAC' for the treatment of Hepatitis 'B' virus. A pharmaceutical company in this country will prepare and market the medicines. Its price is low and readily available in the market compared to other medicines of hepatitis B.

Professor Dr. Mamun-al-Mahtab said, "NASAVAC is not a magical drug. But in clinical trials of this drug, positive results were found in 50% of the patients with hepatitis B virus. And the treatment rate of patients with liver inflammation is 100 percent.

Dr. Mahtab is the chief tester of the validity of this drug and Dr. Akbar completed basic research for the invention of this drug.

Professor Akbar, a expatriate Bangladeshi lever specialist in Japan, has been researching new healing methods for hepatitis B treatment for the last 25 years. The main objective of his research is to control the virus by increasing the human immune system against hepatitis B.

Dr. Akbar first researched the mouse. After conducting clinical examination on hepatitis B patients with the approval of the Japanese Health Ministry and Education Ministry. Later on for further research. Mahtab created a database of about 1,000 hepatitis B patients in Bangladesh.

In 2009, the first and second clinical trials of NASAVAC were conducted on 18 chronic hepatitis 'B' patients in Bangladesh. As a result, in 2011, again 151 patients were given clinical trials.

In the third phase, these 151 Chronic Hepatitis B patients are divided into two groups, respectively, treated with 'NASAVAC' and paginated interferons. Total trials include 75 patients with a total of 15 times 'nasavac' and 76 other patients have been given 48 times pagyletrated interferons.

According to the World Health Organization (WHO), 24 million people in the world are infected with Chronic Hepatitis B virus.

Referring to a scientific research. Mahtab said more than 5 million people in the country are infected with hepatitis B virus. Of these, 80 million people are infected with Chronic Hepatitis B and they have the risk of becoming liver cirrhosis and liver cancer. BSS